In addition, such doses were associated with a ‘near-significant’ 17 percent decrease in the risk of ‘total fatal coronary events’, according to a team of researchers from academia and industry.
Search
News Archive
Categories
algae
alternative energy
aquaculture
Aquapharm
Aquapreneur
astaxanthin
biofuel
biomaterials
bioprocessing
brown seaweed
chitin
chitosan
commercialize
cosmeceuticals
cosmetics
DHA
EPA
fish oil
fish protein
fucoidans
functional food
functional ingredients
glycomar
krill oil
marine biopolymer
marine bioprospecting
marine biotech cluster
marine biotechnology
marine drugs
marine enzymes
marine extract
marine ingredient
marine ingredients
marine microbe
marine natural product
marine organism
marine protein
microalgae
nutraceutical
omega 3
pharmaceutical
seafood byproducts
seaweed
sustainable
technology
Fish Oil May Have Positive Effects on Mood, Alcohol Craving, New Study Shows
Posted On: June 2, 2011Research at the Indiana University School of Medicine disclosed at a molecular level a potential therapeutic benefit between these dietary supplements, alcohol abuse and psychiatric disorders.
In a multi-year study, researchers showed conclusive behavioral and molecular benefits for omega 3 fatty acid given to mice models of bipolar disorder. The fatty acid DHA, which is one of the main active ingredients in fish oil, “normalized their behavior,” according to Alexander B. Niculescu, M.D., Ph.D., associate professor of psychiatry and the lead author of the study reported online in the Nature Publishing Group journal Translational Psychiatry.
Using a stress-sensitive mouse model of bipolar disorder developed in his lab, Dr. Niculescu and his colleagues studied the influence of dietary DHA. The mice have characteristic bipolar symptoms including being depressed and, when subjected to stress, becoming manic.
“The mice that were given DHA normalized their behavior, they are not depressed and when subjected to stress, they do not become manic,” said Dr. Niculescu. “When we looked into their brains, using comprehensive gene expression studies, we were surprised to see that genes that are known targets of psychiatric medications were modulated and normalized by DHA.”
An unexpected finding of the research was the discovery that the mice given DHA also showed a reduced desire for alcohol.
From Issue 14 • Categories: Tags: Aquapreneur, DHA, EPA, fish oil, functional ingredients, omega 3, seafood byproducts • No Comments
New Fish Sausage Product from Frutarom
Posted On: June 2, 2011Frutarom Savory Solutions GmbH has developed a compound for sausage from fish which neatly links the popular consumer trends for snacking and following a healthy diet. The fish version is considerably lower in fat than conventional sausage from pork or beef and contains valuable omega-3 fatty acids. Selected natural ingredients ensure that the end product has a pleasant spiciness and texture.
With this compound, Frutarom Savory Solutions has developed a product that allows manufacturers to present fish in a new form. It is available in several varieties containing different seasonings, and only has to be mixed with minced fish, oil, ice and salt to form a homogeneous mass which is then processed into sausage. Manufacturing is quite simple, but requires a cutter and a sausage filler. In addition to the compound, Frutarom Savory Solutions is offering a recipe and a curry sauce which enables the sausage to be presented in the style of the popular German “Currywurst” snack.
The fish sausage compound has high temperature- and freeze-thaw stability and is thus particularly suitable for manufacturers of convenience, restaurant chain and canteen meals. The innovative product also enables catering companies and producers of delicacies to extend their fish portfolio.
From Issue 14 • Categories: Tags: Aquapreneur, fish sausage, Frutarom, functional food, marine ingredients, omega 3, seafood byproducts, seafood sausage • No Comments
Dose threshold for omega-3 heart benefits studied
Posted On: June 2, 2011Daily doses of omega-3s of at least 250 milligrams are required to reduce the risk of sudden cardiac death and other heart conditions, says a new review and meta-analysis.
According to findings published in the British Journal of Nutrition, at least 250 mg of the long-chain omega-3 fatty acids (LCFA), eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), was associated with a 35 percent reduction in the risk of sudden cardiac death.
From Issue 14 • Categories: Tags: Aquapreneur, DHA, EPA, fish oil, marine biotechnology, marine extract, marine ingredient, marine ingredients, nutraceutical, omega 3, seafood byproducts • No Comments
GC Rieber Oils to market fish oil products under new VivoMega brand name
Posted On: May 18, 2011GC Rieber Oils recently announced that it will sell its fish oil products under the brand name VivoMega™. A recent major initiative by the company to build a new factory that will produce high quality fish oil concentrates of Omega-3 has led to new markets opening up, and thus the company’s desire to be more marketing-driven. Once only selling traditional fish oils, GC Rieber now has become a total supplier, and has therefore decided to position itself by selling all their products under the brand name VivoMega™
VivoMega™ will be launched on www.vivomega.com.
From Issue 14 • Categories: Tags: Aquapreneur, DHA, EPA, fish oil, GC Rieber, marine ingredient, marine ingredients, nutraceutical, omega 3, VivoMega • No Comments
Omega-3 may slash levels of heart disease risk factor
Posted On: May 6, 2011Supplements of omega-3 fatty acids are associated with lower levels of an amino acid called homocysteine, an amino acid linked to increased risks of heart disease and dementia, says a new meta-analysis of the scientific evidence.
Data from 11 trials including 720 people with doses of omega-3 ranging from 0.2 to 6 grams per day concluded that supplementation with omega-3s was associated with lower blood levels of homocysteine.
“Our systematic review provides, to our knowledge, the most comprehensive assessment to date of the effects of omega-3 PUFAs on plasma homocysteine,” wrote the researchers in Nutrition.
Researchers from China, Taiwan, and Australia added that a more comprehensive analysis would benefit from additional rigorous and long term trials. They also noted that such trials should also seek to measure whether the reduction in homocysteine levels actually produces an important health effect, such as a reduction in heart disease.
From Issue 14 • Categories: Tags: Aquapreneur, DHA, EPA, fish oil, marine biotechnology, marine ingredient, marine ingredients, marine natural product, nutraceutical, omega 3, PUFA, seafood byproducts • No Comments
Bayer Healthcare’s Arctic Wonder market test succeeds with Neptune Krill Oil, leading to launch
Posted On: April 15, 2011Neptune Technologies & Bioressources Inc. announced recently that Bayer Healthcare, LLC Consumer Care Division has formally launched its Arctic Wonder proprietary Neptune Krill Oil (“NKO”) in the United States in March 2011 after a succesful market test.
Bayer’s market test conducted over the last year with NKO® under its Arctic Wonder brand was performed in the US internet direct response e-commerce channel of trade.
“Acasti management team, is delighted by the relationship Neptune has developed with Bayer. This is yet another significant milestone for Neptune’s strategic planning which will help NKO® achieve extensive consumer awareness and appreciation. We are looking forward to a successful long-term collaboration with Bayer”, stated Dr. Tina Sampalis, President of Acasti Pharma.
“The agreement with Bayer, the market test results and the marketing approach for Arctic Wonder NKO® not only create broad consumer awareness, confidence and appreciation but also distinguish NKO® as the superior and prime choice amongst competitor krill oil products”, said Mr. Henri Harland, President and CEO of Neptune.“Arctic Wonder is entering the rapidly growing omega-3 market which has shown a sustained annual growth of 12% according to the Frost and Sullivan Report 2010. The omega-3 category is valued at $1.7 billion and expected to reach $3.5 billion in 2015. We believe the full launch by Bayer of Arctic Wonder will achieve immediate success which will in turn positively influence our growth and increase Neptune’s krill oil market share, reinforcing Neptune’s position as the industry leader and Neptune Krill Oil as the gold standard of quality and efficacy for krill oil products in the market.” he added.
From Issue 14 • Categories: Tags: Acasti Pharma, Aquapreneur, Arctic Wonder, commercialize, DHA, EPA, fish oil, functional ingredients, krill oil, marine biotechnology, marine ingredients, Neptune Technologies & Bioresources, NKO, nutraceutical, omega 3, pharmaceutical, seafood byproducts • No Comments
Aurora Algae has announced the launch of new A2 product portfolio, including omega-3 products
Posted On: April 15, 2011Aurora Algae recently introduced the A2 product portfolio, a series of natural products derived from its proprietary algae platform. The A2 product portfolio is uniquely sustainable, scalable, and flexible to address growing demand in the explosive nutrition, aquaculture, pharmaceutical, and energy markets
A2 Omega-3™ is a family of Omega-3 oils aimed at the nutraceutical and pharmaceutical markets with the goal of providing a natural, sustainable and cost-effective alternative to fish oil and fermented products. The first offering in this family, A2 EPA Pure™ will make the benefits of EPA available to a broader market since it is derived from an allergen-free, vegetarian source.
From Issue 14 • Categories: Tags: A2, A2 EPA Pure, A2 Omega-3, algae, aquaculture, Aquapreneur, Aurora Algae, bioprocessing, DHA, EPA, fish oil, fish protein, functional food, functional ingredients, marine ingredients, omega 3, sustainable • No Comments
New algae-derived EPA to target pharma omega-3 market
Posted On: April 15, 2011New Zealand-based Photonz Corporation has signed an agreement with Separex to develop a pharma-grade EPA omega-3 manufacturing process from fermented microalgal biomass.
Under the agreement, Separex, under a license of Stanipharm, will develop a manufacturing process, scalable to industrial volumes, to concentrate the Omega-3 fatty acid, eicosapentaenoic acid (EPA), which Photonz extracts from fermented microalgal biomass.
Photonz’s proprietary processes produce the EPA by fermenting a marine microalgal clone (improved by strain selection not genetic engineering) to produce a biomass rich in lipids from which it extracts the Omega-3.
The agreement follows two other significant achievements, announced last year, in which Photonz proved the feasibility of its continuous fermentation system and then harvested the first batch of algal biomass from its prototype industrial plant. The plant is now producing on a small industrial scale and has the potential to produce tonnes of algal material per year. The lipids it produces will be used by Separex to produce concentrated EPA. Photonz is, in parallel, targetting the development of downstream purification processes to produce high purity EPA, suitable for pharmaceutical applications, including novel therapeutics.
From Issue 14 • Categories: Tags: algae, Aquapreneur, bioprocessing, DHA, EPA, fish oil, functional ingredients, marine drugs, marine ingredient, marine ingredients, microalgae, microalgal biomass, omega 3, Photonz, Separex • No Comments
Martek Applies for Novel Food Approval for New DHA and EPA Rich Algal Oil
Posted On: April 6, 2011Martek Biosciences Corporation has applied to the UK Food Standards Agency for approval to market algal oil that is produced from Schizochytrium microalgae, as a novel food ingredient. A novel food is a food or food ingredient that does not have a significant history of consumption within the European Union before 15 May 1997.
Martek has previously gained approval to use docosahaexanoic acid (DHA)-rich oil, produced from the algae Schizochytrium sp, as a novel food ingredient. Martek has now developed an improved strain from another species of Schizochytrium microalgae that produces an oil rich in both DHA and eicosapentaenoic acid (EPA). The oil is known as DHA-O.
From Issue 14 • Categories: Tags: algae, DHA, EPA, fish oil, functional ingredients, marine biotechnology, marine ingredient, marine ingredients, Martek, microalgae, omega 3 • No Comments
Eskimo study supports omega-3 for heart health
Posted On: March 28, 2011High intakes of omega-3 fatty acids may reduce the risk of obesity-related chronic diseases such as diabetes and heart disease, according to new findings from a study with Alaskan Eskimos.
Yup’ik Eskimos, the most famous indigenous people of the US’ 49th State, have similar obesity rates to the lower 48 states, but the incidence of type-2 diabetes is only 3.3 percent, compared with 7.7 percent nationally.
According to researchers from the Fred Hutchinson Cancer Research Center and the University of Alaska-Fairbanks, this apparent reduction in diabetes risk is linked to the observation that the Eskimos’ average consumption of omega-3s from fish is 20 times more than people in the lower 48 states.
The new study, published in the European Journal of Clinical Nutrition, echoes findings from the first studies in this area from 40 years ago, carried out by Dr Jørn Dyerberg and his Danish colleagues amongst the Inuit of Greenland. The Danish scientists sought to understand how the Greenland Eskimos, or Inuit, could eat a high fat diet and still have one of the lowest death rates from cardiovascular disease on the planet.
Host
 |
Partners
  |
Sponsors
 |
 |
Share Aquapreneur
